Safety, Tolerability, and Pharmacokinetics of Multiple Novel Insulin Lispro Formulations
Safety, Tolerability, and Pharmacokinetics of Multiple Novel Insulin Lispro Formulations
The purposes of this study are to determine:
Part A
Part B:
Participants may only enroll in one part. The study is expected to last up to 10 weeks for each part.
Inclusion Criteria:
- Overtly healthy males or females (non-childbearing potential and with absent cyclical hormonal changes), as determined by medical history and physical examination
Exclusion Criteria:
- Have a fasting plasma glucose less than or equal to (≤) 4.0 millimole per liter (mmol/L) at screening